LC-MS/MS法测定吡非尼酮在大鼠体内的药动学参数被引量：1

LC-MS/MS method for the determination of pirfenidone in rat plasma and its pharmacokinetics

下载PDF

导出

摘要目的建立灵敏的液相色谱-串联质谱（LC-MS/MS）法测定大鼠血浆中吡非尼酮的浓度。方法血浆样品采用乙腈蛋白沉淀方法,色谱柱为Dikma Diamonsil C18;以0.1%甲酸-乙腈（45：55,v/v）为流动相;流速为0.4 m L·min-1;柱温为30℃。结果吡非尼酮血药浓度在5-2000 ng·m L-1内线性关系良好（r=0.9995）,最低检测限为5 ng·m L-1;日内、日间RSD均≤10%,高、中、低3种浓度的回收率均在93%左右。6只SD大鼠单剂量口服给予吡非尼酮后药动学参数分别为：Cmax（1354.3±143.5）ng·m L-1;t1/2（2.21±0.24）h;AUC0-t（3474.6±982.5）h·ng·m L-1;AUC0-∞（3687.4±992.4）h·ng·m L-1。结论本方法简便、准确、灵敏、专属性强,同样适用于人血浆中吡非尼酮浓度的测定及其药动学研究,对于评价吡非尼酮疗效和安全性有重要意义。 Objective To establish a sensitive LC-MS/MS method to determine pirfenidone in rat plasma. MethodsChromatographic analysis was carried out on a Dikma Diamonsil C18 column with the mobile phase of 0.1% formic acid and acetonitrile（45 ：55, v/v） at flow rate of 0.4 m L·min- 1. The temperature of column was 30 ℃. ResultsThe calibration was linear at 5- 2000 ng·m L- 1 for pirfenidone. The inter- and intra-day precision was less than 10%. The recovery was 93%. The pharmacokinetic parameters were： Cmax（1354.3±143.5） ng·m L-1; t1/2（2.21±0.24） h; AUC0 - t（3474.6±982.5） h·ng·m L- 1; and AUC0 -∞（3687.4±992.4） h·ng·m L- 1. Conclusion This simple, accurate, sensitive and specific method can be used in routine clinical practice to monitor pirfenidone concentrations in human plasma.

作者许勇王闰

机构地区解放军第八五医院药剂科

出处《中南药学》 CAS 2015年第9期919-922,共4页 Central South Pharmacy

关键词吡非尼酮 LC-MS/MS 药动学 pirfenidone LC-MS/MS pharmacokinetics

分类号 R969.1 [医药卫生—药理学]

引文网络
相关文献

参考文献14

1Karimi-Shah BA,Chowdhury BA.Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib[J].N Engl J Med,2015,372(13):1189-1191.
2Cottin V,Maher T.Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis[J].Eur Respir Rev,2015,24(135):58-64.
3Duck A,Pigram L,Errhalt P,et al.IPF care:a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe[J].Adv Ther,2015,32(2):87-107.
4Chen JF,Liu H,Ni HF,et al.Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats[J].Plos One,2013,8(12):e83593.
5Conte E,Gili E,Fagone E,et al.Effect of pirfenidone on proliferation,TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts[J].Eur J Pharm Sci,2014,58:13-19.
6Gurujeyalakshmi G,Hollinger MA,Giri SN.Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level[J].Am J Physiol,1999,276(2 Pt 1):L311-318.
7Takeda Y,Tsujino K,Kijima T,et al.Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis[J].Patient Prefer Adherence,2014,8(2):361-370.
8Wang YS,Zhao XP,Zhong J,et al.Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography[J].Biomed Chromatogr,2006,20(12):1375-1379.
9Shi SJ,Wu JH,Wu J,et al.Development and validation of an improved LC method for the simultaneous determination of pirfenidone and its carboxylic acid metabolite in human plasma[J].Chromatographia,2009,69:459-463.
10Huang NY,Ding L,Wang J,et al.Pharmacokinetics,safety and tolerability of pirfenidone and its major metabolite aftersingle and multiple oral doses in healthy Chinese subjects under fed conditions[J].Drug Res,2013,63(8):388-395.